Mammalian target of rapamycin (mTOR) inhibition in advanced bronchial carcinoids

Nicola Fazio, Anna Maria Frezza

Research output: Contribution to journalArticlepeer-review


Bronchial carcinoids (BCs), comprising typical (TC) and atypical (AC) carcinoids, account for 1-2 % of all lung cancers and approximately 20-30 % of all neuroendocrine neoplasms (NENs). They represent the low- and intermediate-grade lung NENs, whereas small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) represent the high-grade entities. While the prognosis of BCs is favourable at early stages, it is poor when distant metastases are present. Unfortunately, there is a lack of therapeutic options as well as limited data to support the use of standard therapies and sequences of treatments. Some chemotherapeutic regimens have been reported to be active, but their efficacy has not been validated so far. Somatostatin analogues (SSAs) as single agents can be an option for very slow-growing disease, but their role in combination with other therapies has not been established. Among the new targeted agents, data from clinical trials showed that everolimus is a promising one.

Original languageEnglish
Pages (from-to)100-104
Number of pages5
JournalEuropean Oncology and Haematology
Issue number2
Publication statusPublished - 2015


  • Bronchial carcinoid
  • Bronchopulmonary carcinoid
  • Carcinoid tumour
  • Everolimus
  • Large cell neuroendocrine carcinoma
  • Lung NET
  • Lung neuroendocrine tumour
  • Pulmonary neuroendocrine neoplasm
  • Small cell lung cancer
  • Somatostatin analogue

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Mammalian target of rapamycin (mTOR) inhibition in advanced bronchial carcinoids'. Together they form a unique fingerprint.

Cite this